Sensitivity of Abi1/Pten null tumors to taxane and anti-androgen receptor therapy

Abi1/Pten 无效肿瘤对紫杉烷和抗雄激素受体治疗的敏感性

基本信息

批准号：
10430168
负责人：
LESZEK KOTULA
金额：
$ 18.56万
依托单位：
UPSTATE MEDICAL UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-06-15 至 2024-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10430168
关键词：
1-Phosphatidylinositol 3-Kinase Actins American Anatomy Androgen Antagonists Androgen Receptor Androgens Antiandrogen Therapy Apoptosis Biochemical Biopsy CDH1 gene Cadherins Cancer Etiology Cell Nucleus Cell membrane Cell-Cell Adhesion Cessation of life Clinical Clinical Treatment Complex Data Disease Dissection Down-Regulation Drug usage Epithelial FYN gene FZD2 gene Gene Expression Gene Expression Profile Genes Genetic Genetic Transcription Genetically Engineered Mouse Goals Histology Human Immunohistochemistry Indolent Knockout Mice Knowledge Ligands Literature MMP2 gene Malignant Neoplasms Malignant neoplasm of prostate Mediating Mesenchymal Metastatic Prostate Cancer Metastatic to Microdissection Modeling Mus Nonmetastatic Organoids Outcome PTEN gene Pathway interactions Patient-Focused Outcomes Patients Pharmaceutical Preparations Pharmacotherapy Prostate Prostate Cancer therapy Publishing Quality of life RNA analysis Receptor Inhibition Research Resistance Role STAT3 gene Signal Transduction Small Interfering RNA Survival Rate Therapeutic Treatment Protocols Treatment outcome Tumor Biology Tumor Burden Tumor Markers Tumor Suppressor Genes Tumor Tissue Tumor Weights Up-Regulation WNT5A gene Xenograft Model advanced prostate cancer androgen deprivation therapy base cancer diagnosis candidate marker chemotherapy deprivation docetaxel drug sensitivity enzalutamide human model improved inhibitor male men new therapeutic target novel personalized medicine polymerization precision medicine prostate cancer model prostate cancer progression receptor receptor function response senescence synergism targeted agent targeted cancer therapy taxane therapy resistant transcriptome sequencing translational study treatment strategy tumor tumor growth ultrasound

项目摘要

ABSTRACT Prostate cancer (PCa) is the most frequently diagnosed cancer in American men and the 2nd leading cause of male cancer-related deaths in the U.S. Indolent localized PCa is curable, but metastatic PCa is fatal. Progression to metastatic disease is characterized by reactivation of androgen signaling including androgen receptor (AR) function. This knowledge led to anti-androgen pathway therapy which is a mainstay for treatment of progressive PCa. Unfortunately, patients eventually become resistant to anti-androgen therapy and the benefit of subsequent taxane-based chemotherapy is limited to only extending patient survival for up to a year. An urgent need for identification of novel actionable targets remains. The long-term goal of this project is to develop better treatment strategies and rational drug therapies for precision medicine in advanced PCa. Our previous studies demonstrated ABI1 as a bona fide PCa tumor suppressor gene. ABI1 downregulation promotes epithelial mesenchymal transition (EMT) downstream from activation of the non-canonical WNT- FYN-STAT3 pathway. Our published and preliminary data indicate that ABI1 downregulation, in conjunction with loss of PTEN, is associated with high grade and metastatic PCa in a significant subset of human PCa. Because ABI1 expression is downregulated following androgen deprivation therapy, we hypothesize that anti- AR treatment leads to activation of the WNT-FYN-STAT3 pathway. Moreover, taxane therapies might promote activation of the WNT pathway and potentially cause cross-pathway effects with anti-AR treatment. Our objective is to develop a more comprehensive understanding of the contribution of ABI1 and PTEN on tumor sensitivity to the current treatment regimen of androgen receptor (AR)-targeting agents for both castrate- sensitive (CSPC) and resistant (CRPC) PCa, as well as druggability of the ABI1/PTEN pathway itself. Our central hypothesis is that ABI1-deficient tumors have a low sensitivity to anti-AR agents. In addition, we propose that ABI1-deficient tumors are sensitive to STAT3 pathway inhibitors. We propose that ABI1 is a candidate marker of tumor sensitivity for current treatments of PCa. Using the novel Abi1/Pten null mouse and organoid prostate models, we will assess drug sensitivity and characterize the tumor response in search for treatment resistance targets. We aim to: 1) Determine sensitivity of Abi1/Pten null tumors to AR inhibition (using enzalutamide) or taxane chemotherapy (using cabazitaxel) before and after androgen deprivation; 2) determine sensitivity of Abi1/Pten null tumors to STAT3 inhibition and synergy with AR inhibition (enzalutamide) or taxane (cabazitaxel) chemotherapy. Tumor gene expression patterns will be analyzed by RNA-Seq. Identified drug response-pathways will be studied using organoid and xenograft models of human metastatic PCa lacking ABI1 and PTEN genes. The expected outcome is a better understanding of ABI1 and PTEN involvement in tumor sensitivity to current therapeutics for advanced PCa, the role for STAT3 inhibition in PCa therapy, and identification of potential targets for overcoming treatment resistance.

抽象的前列腺癌（PCA）是美国男性最常见的癌症，第二个主要原因在美国，与癌症相关的男性死亡顽固性局部PCA可以治愈，但转移性PCA是致命的。向转移性疾病的发展的特征是雄激素信号传导重新激活，包括雄激素受体（AR）功能。这些知识导致了抗雄激素途径疗法，这是治疗的中流渐进式PCA。不幸的是，患者最终对抗雄激素治疗具有抗性随后的基于紫杉烷的化疗的好处仅限于将患者生存延长长达一年。迫切需要确定新型可行目标。该项目的长期目标是在晚期PCA中制定更好的治疗策略和合理的药物疗法。我们的先前的研究表明，ABI1是真正的PCA肿瘤抑制基因。 ABI1下调通过非典型的Wnt-激活下游促进下游的上皮间质转变（EMT） Fyn-STAT3途径。我们发布的初步数据表明，ABI1下调，结合使用随着PTEN的损失，在人类PCA的显着子集中与高级和转移性PCA有关。因为在雄激素剥夺治疗后，ABI1表达被下调，我们假设 AR处理导致Wnt-Fyn-Stat3途径的激活。此外，紫杉烷疗法可能会促进 Wnt途径的激活，并可能通过反AR治疗引起跨道路效应。我们的目的是对ABI1和PTEN对肿瘤的贡献有更全面的了解对雄激素受体（AR）靶向剂的当前治疗方案的敏感性敏感（CSPC）和抗性（CRPC）PCA，以及ABI1/PTEN途径本身的可药物。我们的中心假设是ABI1缺陷肿瘤对抗AR药物的敏感性低。另外，我们提出ABI1缺陷型肿瘤对STAT3途径抑制剂敏感。我们建议ABI1是肿瘤敏感性的候选标记，用于当前PCA的治疗。使用新颖的ABI1/PTEN NULL鼠标和器官前列腺模型，我们将评估药物敏感性并表征寻找肿瘤的反应治疗抗性靶标。我们的目的是：1）确定ABI1/PTEN无肿瘤对AR抑制的敏感性（使用enzalutamide）或紫杉烷化疗（使用cabazitaxel）在雄激素剥夺之前和之后； 2）确定ABI1/PTEN无效肿瘤对STAT3抑制和AR抑制协同作用的敏感性（enzalutamide）或紫杉烷（Cabazitaxel）化学疗法。肿瘤基因表达模式将通过 RNA-seq。将使用人类的类器官和异种移植模型来研究确定的药物反应通道缺乏ABI1和PTEN基因的转移性PCA。预期的结果是对ABI1和 PTEN参与肿瘤对当前治疗剂的晚期PCA敏感性，STAT3抑制作用的作用在PCA疗法中，并鉴定了克服耐药性的潜在靶标。

项目成果

期刊论文数量（3）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Breast Cancer Treatment: To tARget or Not? That Is the Question.

乳腺癌治疗：有目标还是无目标？这就是问题所在。

DOI：
10.3390/cancers15235664
发表时间：
2023-11-30
期刊：
CANCERS
影响因子：
5.2
作者：
Stone, Alexandra;Lin, Kevin M.;Ghelani, Ghanshyam H.;Patel, Sanik;Benjamin, Sam;Graziano, Stephen;Kotula, Leszek
通讯作者：
Kotula, Leszek

Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate Cancer.

DOI：
10.3390/cancers13102426
发表时间：
2021-05-17
期刊：
Cancers
影响因子：
5.2
作者：
Gleicher S;Porter BA;Nath D;Li G;Khanna R;Goldberg H;Kortylewski M;Bratslavsky G;Kotula L
通讯作者：
Kotula L

In Vivo Models for Prostate Cancer Research.